Federal funding for COVID-19 vaccines will stop this year and the provinces and territories will be responsible for buying ...

Shares of Novavax Inc. NVAX shed 3.02% to $9.32 Friday, on what proved to be an all-around rough trading session for the ...

JP Morgan has recently reduced Novavax Inc (NVAX) stock to Underweight rating, as announced on July 30, 2024, according to Finviz. Earlier, on May 10, 2024, JP Morgan had raised the stock from a ...

Novavax Inc. had an impressive 2024, with its stock gaining nearly 68%. The momentum has continued into 2025, with shares up ...

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They ...

Stay updated on the latest potential FDA drug approvals in 2025, including an expanded label for Ozempic and new, nonopioid painkillers.

Novavax shares fell 11.2% during Wednesday's session. Vaccine stocks are volatile after the first US bird flu death and a CDC ...

The Covid-19 positivity rate has also seen a rise to 7.1% this past week, versus the 5.5% figure for the past four weeks.

The stock's fall snapped a five-day winning streak.

Licensing deals have risen in prominence in a restrained market environment. Is it desperation, or an important part of the ...

Novavax Inc (NVAX) stock saw a modest uptick, ending the day at $10.82 which represents a slight increase of $1.06 or 10.86% from the prior close of $9.76. The stock opened at $9.95 and touched a low ...

The U.S. stock market experienced a downturn on Tuesday, with the Nasdaq Composite falling by 1.9% and the S&P 500 dropping by 1.1%..